- Home
- HR vs LEGN Comparison
HR vs LEGN Comparison
Compare HR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HR | LEGN |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HR | LEGN |
|---|---|---|
| Price | $17.44 | $18.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $19.57 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 3.9M | 3.2M |
| Earning Date | 02-12-2026 | 03-10-2026 |
| Dividend Yield | ★ 5.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,204,680,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $67.56 |
| Revenue Next Year | N/A | $45.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $14.09 | $16.24 |
| 52 Week High | $18.97 | $45.30 |
Technical Indicators
Market Signals| Indicator | HR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 42.75 |
| Support Level | $16.68 | $16.82 |
| Resistance Level | $16.84 | $17.38 |
| Average True Range (ATR) | 0.32 | 0.78 |
| MACD | 0.09 | 0.17 |
| Stochastic Oscillator | 97.84 | 61.55 |
Price Performance
Historical ComparisonAbout HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.